Global Crohns Disease Diagnostic and Therapeutic Market Growth, Trends and Forecast 2017 - 2022

  • ID: 4388371
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
The therapeutic and diagnostic market for Crohn’s disease is accounted to $XX billion for the year 2014 and is anticipated to reach $XX billion at a CAGR of XX% by 2020.Crohn’s Disease (CD) is an Inflammatory Bowel’s Disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune and bacterial factors in genetically predisposed individuals. It has been estimated by CDS, Atlanta that around 200 per 100,000 population might be affected with an incidence rate of 3.1 to14.6 cases per 100,000 person years.

The therapeutics of treatment of Crohn’s disease has been segmented to cope with the various symptoms associated with the disease like anti-inflammatory drugs, immunosuppressive drugs and antipyretics to reduce pain. However, with the introduction of new biotherapies like interleukin inhibitors (IL 12/13) and alpha4beta7 inhibitor, the global drug and therapeutic market for CD will undergo a dynamic change in the near future. With the loss of the patent protection of anti TNF based drugs, the void will be a welcoming platform for many new players. The key players in the therapeutics domain of CD are Takeda's Pharmaceutical Ltd, Abbvie, Johnnson and Johnnson, Celgene Corportation, Genetech, Janssen Biotech Inc, Pfizer Inc., Prometheus Laboratories Inc. and many others.


The increase in the number of people being affected along with the chronic nature of the disease has made CD one of the prominent health hazards wanting immediate and prominent diagnostic and therapeutic which will be a major contributor of the market drive.


With the loss of patent protection of anti TNF based drugs and lack of clarity to distinguish it from other common gastrointestinal ailments, the challenge lies in an effective and efficient therapeutic design.

This Report Offers:

1) Market Definition for the specified topic along with identification of key drivers and restraints for the market.

2) Market analysis for the Global Crohn’s Disease Market, with region specific assessments and competition analysis on a global and regional scale.

3) Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

4) Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares

5) Identification and analysis of the Macro and Micro factors that affect the Crohn’s Disease Market on both global and regional scale.

6) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 3
1.1. Study deliveratives
1.2. Market Definition
1.3. Sizing Units
1.4. Base Currency
1.5. Review and forecasr period years
1.6. General Study Assumptions
2.1. Introduction
2.2. Analysis Methodology
2.3. Econometric forecast models
2..4.Research Assumptions
5.1. Current market scenario
5.2. Technology Overview
5.3.New developments in therapeutics
5.4.. Investment analysis
5.5. Porters Five Force Analysis
5.5.1 Bargaining Power of suppliers
5.5.2 Bargaining power of buyers
5.5.3 Degree of competition
5.5.4 Threat of substitution
5.5.5 Threat of new entrants
6.1. Market Drivers
6.1.1. Multiple symptoms associated with the disease requires individual therapeutic attention.
6.1.2. Demand for prompt diagnosis
6.1.3. Affected population increasing with time
6.2. Market Restraints
6.2.1. No specific treatment or drug available in the market.
6.2.2. Lack of awareness among the people and symptom similarity with other gastrointestinal disease.
6.2.3. Lack of a cost effective form of treatment
6.3 Market Opportunities
6.3.1. Emergence of biosimilars
6.3.2. Patent expiry of various useful drugs, such as Remicade and Humira along with anti TNF marketed brands opens
gates for new players
6.4. Key Challenges
7. Global Crohn's Disease Diagnostic and Therapeutic Market by disease type
7.1. Ileocolitis
7.2. Iletis
7.3. Gastroduodenal crohn's
7.4. Jejunoileitis
7.5. Crohn's colitis
8. Global Crohn's Disease Diagnostic and Therapeutic markey by method of diagnosis
8.1. Blood tests
8.2. Fecal test
8.3. Colonoscopy
8.4. Flexible sigmoidoscopy
8.5. Computerized tomography
8.6. Magnetic resonance imaging
8.7. Capsule endoscopy
8.8. Double ballon endoscopy
9. Global Crohn's Disease Diagnostic and Therapeutic markey by method of treatment
9.1. Drugs and Medication
9.1.1. Medication for inflammation
9.1.2. Medication for immunosupression
9.1.3. Medication for pain relief
9.2. Surgery
10. Global Crohn's Disease Diagnostic and Therapeutic markey by Georaphy - Regional shares and forecast
10.1 North America
10.1.1. Introduction
10.1.2. USA
10.1.3. Canada
10.1.4. Rest of North America
10.2 Europe
10.2.1. Introduction
10.2.2. France
10.2.3. UK
10.2.4. Germany
10.2.5. Spain
10.2.6. Russia
10.2.7. Italy
10.2.8. Rest of Europe
10.3 Asia-Pacific
10.3.1. Introduction
10.3.2. India
10.3.3. China
10.3.4. Japan
10.3.5. South Korea
10.3.6. Australia
10.3.7. Rest of Asia Pacific
10.4. Middle East and Africa
10.4.1 Introduction
10.4.2. UAE
10.4.3. Saudi Arabia
10.4.4. Israel
10.4.5. Rest of MEA
10.5. Latin America
10.5.1. Introduction
10.5.2. Brazil
10.5.3. Mexico
10.5.4. Argentina
10.5.5. Rest of Latin America
12.1. Abbvie
12.2. Celgene Corportation
12.3. Genetech
12.4. Janssen Biotech Inc.
12.5. Pfizer Inc.
12.6. Prometheus Laboratories Inc.
12.7. Salix Pharmaceuticals Inc.
12.8. Takeda's Pharmaceutical Ltd.
12.9. Johnnson and Johnnson
13. Analyst outlook for Investment Opportunities
14. Future outlook of the market
8.1 Abbrevations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown